表紙
市場調查報告書

巴西的胰島素注射液製劑市場:2019年∼2023年

Human Insulin Drugs Market in Brazil by Distribution Channel, Product, and Application - Forecast and Analysis 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 916573
出版日期 內容資訊 英文 135 Pages
訂單完成後即時交付
價格
Back to Top
巴西的胰島素注射液製劑市場:2019年∼2023年 Human Insulin Drugs Market in Brazil by Distribution Channel, Product, and Application - Forecast and Analysis 2019-2023
出版日期: 2019年10月16日內容資訊: 英文 135 Pages
簡介

巴西的胰島素注射液製劑市場上,巴西的糖尿病盛行率上升,人口轉換,策略性聯盟等成為成長促進因素,在預測期間內預計將以5%以上的年複合成長率擴大。可是,高額的胰島素注射液製劑,病因不明的I型糖尿病,及取得困難的特定生物標記等要素,可能妨礙在預測期間內巴西的胰島素注射液製劑市場成長。

本報告提供巴西的胰島素注射液製劑市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 胰島素:概要

第7章 市場區隔化:各流通管道

  • 市場區隔:各流通管道
  • 各流通管道比較:市場規模及預測(2018年∼2023年)
  • 零售
  • 醫院
  • 市場機會:各流通管道

第8章 市場區隔化:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 基礎胰島素類似物製劑
  • NPH
  • 市場機會:各產品

第9章 客戶形勢

第10章 市場區隔:各應用領域

  • 市場區隔:各應用領域
  • 各應用領域比較:市場規模及預測(2018年∼2023年)
  • I型糖尿病
  • II型糖尿病
  • 市場機會:各應用領域

第11章 決策架構

第12章 成長要素與課題

  • 市場成長要素
  • 市場課題

第13章 市場趨勢

  • 生物相似藥的出現
  • 供應商的措施增加
  • 技術的進步

第14章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第15章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • Biocon Ltd.
  • Eli Lilly and Co.
  • Novo Nordisk AS
  • Sanofi
  • Wockhardt Ltd.

第16章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第17章 關於TECHNAVIO

目錄
Product Code: IRTNTR32183

About this market

Technavio's human insulin drugs market in brazil market analysis considers sales from basal insulin analog and NPH products. Our study also finds the sales of the human insulin drugs market in brazil in retail and hospital distribution channels. In 2018, the basal insulin analog segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as flexibility of timing and dosing, less fear of dose adjustment, and fewer injections with analogs to achieve their therapeutic effect will play a significant role in the basal insulin analog segment to maintain its market position. Also, our human insulin drugs market in brazil report looks at factors such as rising prevalence of diabetes in Brazil, demographic transition in Brazil, and strategic alliance. However, high cost of human insulin drugs, unknown etiology of type I diabetes, and unavailability of specific biomarkers may hamper the growth of the human insulin drugs market in brazil over the forecast period.

Overview

Demographic transition in brazil

Brazil has undergone rapid demographic, nutritional, and epidemiological transitions, which have led to an increase in the prevalence of diabetes in this region. Currently, the youth demographic forms a significant portion of Brazil's population. Since type I diabetes affects an individual at an incredibly young age, the presence of a large younger demographic provides significant growth opportunities for vendors in the human insulin drugs market in Brazil. This demographic transition in brazil will lead to the expansion of the human insulin drugs market in brazil at a CAGR of over 5% during the forecast period.

Technological advancements

Technological advancements are expected to be one of the key factors for the growth of the human insulin drug market size in Brazil during the forecast period. The availability of novel digital equipment and data-driven devices, such as the connected care insulin delivery system, has fueled the interest of researchers in this area. The major vendors in the market are now focusing on developing novel human insulin drugs through strategic alliances, especially by partnering with research institutes and other healthcare organizations. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the human insulin drugs market in brazil during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the human insulin drugs market in brazil is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human insulin drugs market in brazil manufacturers, that include Biocon Ltd., Eli Lilly and Co., Novo Nordisk AS, Sanofi, and Wockhardt Ltd.

Also, the human insulin drugs market in brazil includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: INSULIN: AN OVERVIEW

PART 07: MARKET SEGMENTATION BY DISTRIBUTION CHANNEL

  • Market segmentation by distribution channel
  • Comparison by distribution channel
  • Retail - Market size and forecast 2018-2023
  • Hospitals - Market size and forecast 2018-2023
  • Market opportunity by distribution channel

PART 08: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Basal insulin analog - Market size and forecast 2018-2023
  • NPH - Market size and forecast 2018-2023
  • Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: MARKET SEGMENTATION BY APPLICATION

  • Market segmentation by application
  • Comparison by application
  • Type I diabetes - Market size and forecast 2018-2023
  • Type II diabetes - Market size and forecast 2018-2023
  • Market opportunity by application

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Advent of biosimilars
  • Increasing initiatives by vendors
  • Technological advancements

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Biocon Ltd.
  • Eli Lilly and Co.
  • Novo Nordisk AS
  • Sanofi
  • Wockhardt Ltd.

PART 16: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 17: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Vendors: Key offerings
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Country market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Health finance indicator in Brazil (1995-2011)
  • Exhibit 10: Timeline of Brazil's unified health system
  • Exhibit 11: Country market: Year-over-year growth 2019-2023 (%)
  • Exhibit 12: Five forces analysis 2018
  • Exhibit 13: Five forces analysis 2023
  • Exhibit 14: Bargaining power of buyers
  • Exhibit 15: Bargaining power of suppliers
  • Exhibit 16: Threat of new entrants
  • Exhibit 17: Threat of substitutes
  • Exhibit 18: Threat of rivalry
  • Exhibit 19: Market condition - Five forces 2018
  • Exhibit 20: Blood glucose control
  • Exhibit 21: Types of human insulin analog
  • Exhibit 22: Distribution channel - Market share 2018-2023 (%)
  • Exhibit 23: Comparison by distribution channel
  • Exhibit 24: Retail - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Retail - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Hospitals - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Unified Health System and funding channels in Brazil
  • Exhibit 28: Hospitals - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Market opportunity by distribution channel
  • Exhibit 30: Product - Market share 2018-2023 (%)
  • Exhibit 31: Comparison by product
  • Exhibit 32: Basal insulin analog - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Basal insulin analog - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: NPH - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: NPH - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Market opportunity by product
  • Exhibit 37: Customer landscape
  • Exhibit 38: Application - Market share 2018-2023 (%)
  • Exhibit 39: Comparison by application
  • Exhibit 40: Type I diabetes - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 41: Type I diabetes - Year-over-year growth 2019-2023 (%)
  • Exhibit 42: Type II diabetes - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 43: Type II diabetes - Year-over-year growth 2019-2023 (%)
  • Exhibit 44: Market opportunity by application
  • Exhibit 45: Mortality by cause (2008)
  • Exhibit 46: Non-communicable disease-related mortality rate (2008)
  • Exhibit 47: Demographic indicators in Brazil (1980-2015)
  • Exhibit 48: Practical phenotypic characteristics used to differentiate between type I and type II diabetes
  • Exhibit 49: Impact of drivers and challenges
  • Exhibit 50: Vendor landscape
  • Exhibit 51: Landscape disruption
  • Exhibit 52: Vendors covered
  • Exhibit 53: Vendor classification
  • Exhibit 54: Market positioning of vendors
  • Exhibit 55: Biocon Ltd. - Vendor overview
  • Exhibit 56: Biocon Ltd. - Business segments
  • Exhibit 57: Biocon Ltd. - Organizational developments
  • Exhibit 58: Biocon Ltd. - Geographic focus
  • Exhibit 59: Biocon Ltd. - Segment focus
  • Exhibit 60: Biocon Ltd. - Key offerings
  • Exhibit 61: Biocon Ltd. - Key customers
  • Exhibit 62: Eli Lilly and Co. - Vendor overview
  • Exhibit 63: Eli Lilly and Co. - Product segments
  • Exhibit 64: Eli Lilly and Co. - Organizational developments
  • Exhibit 65: Eli Lilly and Co. - Geographic focus
  • Exhibit 66: Eli Lilly and Co. - Segment focus
  • Exhibit 67: Eli Lilly and Co. - Key offerings
  • Exhibit 68: Eli Lilly and Co. - Key customers
  • Exhibit 69: Novo Nordisk AS - Vendor overview
  • Exhibit 70: Novo Nordisk AS - Business segments
  • Exhibit 71: Novo Nordisk AS - Organizational developments
  • Exhibit 72: Novo Nordisk AS - Geographic focus
  • Exhibit 73: Novo Nordisk AS - Segment focus
  • Exhibit 74: Novo Nordisk AS - Key offerings
  • Exhibit 75: Novo Nordisk AS - Key customers
  • Exhibit 76: Sanofi - Vendor overview
  • Exhibit 77: Sanofi - Business segments
  • Exhibit 78: Sanofi - Organizational developments
  • Exhibit 79: Sanofi - Geographic focus
  • Exhibit 80: Sanofi - Segment focus
  • Exhibit 81: Sanofi - Key offerings
  • Exhibit 82: Sanofi - Key customers
  • Exhibit 83: Wockhardt Ltd. - Vendor overview
  • Exhibit 84: Wockhardt Ltd. - Business segments
  • Exhibit 85: Wockhardt Ltd. - Organizational developments
  • Exhibit 86: Wockhardt Ltd. - Geographic focus
  • Exhibit 87: Wockhardt Ltd. - Key offerings
  • Exhibit 88: Wockhardt Ltd. - Key customers
  • Exhibit 89: Validation techniques employed for market sizing
  • Exhibit 90: Definition of market positioning of vendors
Back to Top